XRAY's Efficiency Program Meets a Revenue Problem That Cost Cuts Cannot Solve

Dentsply Sirona Inc (XRAY) reports first-quarter 2026 earnings on May 5, 2026, with analysts expecting $0.28 per share—a sharp 34.88% decline from the $0.43 reported in the same quarter last year. The dental equipment and consumables manufacturer faces mounting pressure after missing estimates in two of its last three quarters, while technical indicators flash warning signals across all timeframes and the stock trades below every major moving average heading into the release.

Part 1: Earnings Preview

Dentsply Sirona is a leading manufacturer of dental equipment, consumables, and technology solutions, serving dental professionals and laboratories worldwide through its Essential Dental Solutions and Wellspect Healthcare segments. The company reports first-quarter 2026 results on May 5, 2026, with the consensus estimate calling for earnings of $0.28 per share. The company most recently reported fourth-quarter 2025 earnings of $0.27 per share. Compared to the $0.43 reported in the first quarter of 2025, the current estimate represents a significant 34.88% year-over-year decline, reflecting ongoing headwinds in the dental market.

Three key themes define this earnings story. Margin Pressure and Restructuring Execution remains front and center as investors assess whether cost-cutting initiatives can offset volume weakness and pricing challenges in a difficult demand environment. End-Market Demand Stabilization is critical—analysts are watching for signs that destocking in the dental distribution channel has bottomed and that procedure volumes are stabilizing after prolonged softness. Geographic Mix and China Exposure continues to weigh on sentiment, with particular focus on whether weakness in international markets, especially China, is moderating or accelerating.

Analyst commentary ahead of the release reflects cautious positioning. The consensus has been revised downward significantly, with estimates for the current quarter dropping from $0.43 to $0.28 over recent months. The 9 analysts covering the quarter show a wide range of expectations, from a low of $0.22 to a high of $0.40, indicating substantial uncertainty about near-term performance. For the full year 2026, the consensus of $1.43 represents a 10.63% decline from the prior year's $1.60, though 2027 estimates show a modest recovery to $1.56, suggesting analysts expect stabilization but not a robust rebound.

Part 2: Historical Earnings Performance

Dentsply Sirona's recent earnings track record shows significant volatility and a concerning trend of deteriorating execution. The company delivered a strong 48.28% beat in the first quarter of 2025, reporting $0.43 against a $0.29 estimate, followed by a modest 4.00% beat in the second quarter with $0.52 versus $0.50 expected. However, momentum reversed sharply in the back half of the year—the company missed by 17.78% in the third quarter, delivering $0.37 against a $0.45 estimate, and followed with a 3.57% miss in the fourth quarter, reporting $0.27 versus $0.28 expected.

This pattern reveals a company that started 2025 with positive momentum but faced mounting challenges as the year progressed. The dramatic swing from a 48% beat to consecutive misses suggests either deteriorating business fundamentals or overly optimistic analyst expectations that failed to adjust quickly enough to changing conditions. The magnitude of the third-quarter miss was particularly notable, indicating execution challenges or market headwinds that caught both management and analysts off guard. With the current quarter's estimate calling for $0.28—matching the disappointing fourth-quarter result—investors will be watching closely to see whether the company can stabilize performance or if further deterioration lies ahead.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Dentsply Sirona typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Dentsply Sirona's earnings reveals extreme volatility, with an average absolute Day 0 move of 9.64% and Day +1 move of 3.55%. The most dramatic reaction came in November 2024, when the stock plunged 28.02% on Day 0 ahead of results, followed by a modest 3.48% recovery the next day—suggesting severe anticipatory selling that proved overdone. More recently, the February 2026 report saw relatively muted Day 0 movement of just 0.70%, but a substantial 15.50% surge on Day +1, indicating results or guidance that significantly exceeded depressed expectations.

The pattern shows Day 0 moves averaging 9.64% with an 8.09% intraday range, while Day +1 moves average 3.55% with a 5.88% range. This suggests the stock experiences significant volatility in anticipation of results, with follow-through action the next day often providing additional movement. The wide dispersion of outcomes—from a 28% Day 0 decline to a 16% Day 0 gain—indicates that positioning and sentiment heading into each release play a major role in determining the initial reaction, making this a high-risk, high-volatility event for traders.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.08% for the May 15 expiration, which is substantially higher than the 9.64% average Day 0 move and well above the 3.55% average Day +1 move observed historically. This elevated implied volatility of 104.22% suggests options traders are bracing for an outsized reaction, potentially reflecting heightened uncertainty around the company's ability to meet already-lowered expectations or deliver guidance that could stabilize sentiment.

Part 3: What Analysts Are Saying

Analyst sentiment on Dentsply Sirona remains decidedly cautious, with a consensus rating of 3.11 on the five-point scale—firmly in Hold territory—and an average price target of $13.90 that implies 24.11% upside from the current $11.20 price. The rating distribution shows a divided Street: 3 Strong Buys and 13 Holds are offset by 2 Strong Sells, with no Moderate Buy or Moderate Sell ratings, indicating polarized views on the stock's prospects. Price target estimates range widely from a low of $10.00 to a high of $18.00, reflecting substantial disagreement about the company's valuation and recovery potential.

Sentiment has deteriorated over the past month, with the number of Strong Sell ratings increasing from 1 to 2 while the consensus rating slipped from 3.24 to 3.11. This downward revision suggests analysts are growing more cautious as the earnings release approaches, likely reflecting concerns about the company's ability to meet expectations after consecutive misses in the second half of 2025. The 24% implied upside to the $13.90 average target provides some cushion, but the presence of a $10.00 low-end target—below the current price—indicates at least some analysts see further downside risk if execution continues to disappoint.

Part 4: Technical Picture

Dentsply Sirona's technical setup heading into earnings is decidedly bearish, with the Barchart Technical Opinion registering an 88% Sell signal—a dramatic intensification from 48% Sell one week ago and 72% Sell one month ago. This sharp deterioration in technical sentiment reflects accelerating downside momentum as the stock has broken below key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downside pressure and negative momentum
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term weakness, though less extreme than the short-term reading
• Long-term (100% Sell): Maximum bearish signal confirms the longer-term trend has decisively turned negative

Trend Characteristics: The combination of Soft strength and Strongest direction indicates a persistent downtrend that lacks sharp volatility but maintains consistent selling pressure—a technically challenging environment for any bullish reversal attempt around earnings.

The stock's position relative to moving averages reinforces the bearish technical picture: XRAY trades at $11.20, below the 5-day moving average of $11.60, below the 10-day at $11.83, below the 20-day at $11.95, below the 50-day at $12.14, below the 100-day at $12.16, and below the 200-day at $12.60. This complete breakdown below all major moving averages, with each successive average stacked above the current price, defines a textbook downtrend structure. The nearest resistance sits at the 5-day moving average of $11.60, while the 200-day at $12.60 represents a significant overhead barrier. With no technical support from moving averages and all timeframes flashing sell signals, the setup is decidedly cautionary heading into earnings—any positive surprise would need to be substantial to overcome the weight of negative technical momentum, while a miss or weak guidance could accelerate the existing downtrend.